Filed pursuant to Rule 424(b)(3)
Registration No. 333-264447
PROSPECTUS SUPPLEMENT
(to Prospectus dated June 23, 2022)
Terran Orbital Corporation
Up to 140,155,860 Shares of Common Stock
Up to 7,800,000 Warrants to Purchase Shares of Common Stock at $11.50 per Share
Up to 11,055,606 Warrants to Purchase Shares of Common Stock at $10.00 per Share
Up to 19,299,960 Shares of Common Stock Underlying Warrants to Purchase at $11.50 per Share
Up to 11,055,606 Shares of Common Stock Underlying Warrants to Purchase at $10.00 per Share
This prospectus supplement supplements the prospectus dated June 23, 2022 (as supplemented, the Prospectus), which forms a
part of our registration statement on Form S-1 (No. 333-264447). This prospectus supplement is being filed to update and supplement the information in the Prospectus
with certain information in Part I, II and III of Terran Orbital Corporations Annual Report on Form 10-K for the year ended December 31 2022, which was filed with the Securities and Exchange
Commission on March 23, 2023 and is set forth below.
The Prospectus and this prospectus supplement relate to the offer and sale from
time to time by the selling securityholders named in the Prospectus (the Selling Securityholders) of (A) up to 140,155,860 shares of our common stock, par value $0.0001 per share (our common stock), consisting of
(i) up to 5,080,409 shares of our common stock (the PIPE Shares) issued at a purchase price of $10.00 per share in a private placement pursuant to subscription agreements each entered into on October 28, 2021 (the PIPE
Financing); (ii) up to 8,100,000 shares of our common stock (the Founder Shares) issued in connection with the consummation of the Business Combination (as defined in the Prospectus), in exchange for Class B ordinary shares
originally issued at a price of approximately $0.003 per share in a private placement to Tailwind Two Sponsor LLC (the Sponsor) and Tommy Stadlen; (iii) up to 94,952,441 shares of our common stock issued or issuable to certain
Selling Securityholders that are former stockholders and equity award holders of Terran Orbital (the Legacy Terran Orbital equity holders) in connection with or as a result of the consummation of the Business Combination, consisting of
(a) up to 83,481,806 shares of our common stock originally issued to Legacy Terran Orbital stockholders at a weighted-average purchase price of approximately $0.29 per share, after giving effect to the exchange ratio in the Business
Combination; (b) up to 82,616 shares of our common stock issuable upon the exercise of certain options with a weighted-average exercise price of $1.41 per share; and (c) up to 11,388,019 shares of our common stock that certain Legacy
Terran Orbital equity holders have the right to receive upon the settlement of outstanding vested and unvested restricted stock unit awards upon certain conditions; (iv) up to 8,420,569 shares of our common stock issued to certain debt holders
pursuant to a stock and warrant purchase agreement, which were originally issued as non-cash consideration for entering into the Francisco Partners Facility (as defined in the Prospectus) and Rollover Notes
(as defined in the Prospectus); (v) up to 7,800,000 shares of our common stock issuable upon the exercise of the private placement warrants (as defined below); (vi) up to 11,055,606 shares of our common stock issuable upon the exercise of the debt
provider warrants (as defined below); and (vii) up to 4,746,835 shares of our common stock issuable pursuant to the subscription agreement for the Insider PIPE Investor (as defined below) (with the total shares of our common stock referenced in
this clause (A) being referred to herein as the Total Resale Shares); (B) up to 7,800,000 warrants (the private placement warrants) originally issued in a private placement to the Sponsor at a price of $1.50 per warrant,
which private placement warrants have an exercise price of $11.50 per share; and (C) up to 11,055,606 warrants originally issued in a private placement to certain debt providers as non-cash consideration
for entering into the Francisco Partner Facility and Rollover Notes, which debt provider warrants have an exercise price of $10.00 per share (the debt provider warrants and together with the private placement warrants, the Offered
Warrants).
In addition, the Prospectus and this prospectus supplement relate to the offer and sale by us of up to: (A) 11,499,960
shares of our common stock that are issuable by us upon the exercise of 11,499,960 warrants at a price of $11.50 per share (the public warrants and, together with the Offered Warrants, the Warrants) originally issued in
Tailwind Twos (as defined in the Prospectus) initial public offering (the IPO) of units at a price of $10.00 per unit, which each unit consisting of one Class A ordinary share and
one-third of one public warrant; (B) 7,800,000 shares of our common stock that are issuable by us upon the exercise of the private placement warrants at a price of $11.50 per share; and (C) 11,055,606 shares
of our common stock that are issuable by us upon the exercise of the debt provider warrants at a price of $10.00 per share.
Our common
stock and public warrants are listed on the New York Stock Exchange (the NYSE) under the symbols LLAP and LLAP WS, respectively. On March 22, 2023, the last reported sales price of our common stock was $1.59
per share and the last reported sales price of our public warrants was $0.22 per warrant.
We are an emerging growth company
as defined in Section 2(a) of the Securities Act of 1933, as amended, and, as such, have elected to comply with certain reduced disclosure and regulatory requirements.
This prospectus supplement updates and supplements the information in the Prospectus and is not complete without, and may not be delivered or
utilized except in combination with, the Prospectus, including any amendments or supplements thereto. This prospectus supplement should be read in conjunction with the Prospectus and if there is any inconsistency between the information in the
Prospectus and this prospectus supplement, you should rely on the information in this prospectus supplement.
Investing in our
common stock or warrants involves risks. See the section entitled Risk Factors beginning on page 12 of the Prospectus to read about factors you should consider before buying our securities.
Neither the Securities and Exchange Commission nor any state securities commission has approved or disapproved of these securities or
determined if this prospectus supplement or the Prospectus is truthful or complete. Any representation to the contrary is a criminal offense.
The date of
this prospectus supplement is March 23, 2023.